ZombieHealthcare
What Happened to SAB Biotherapeutics?
Ticker: SABSSPAC Year: 2021
Return
-60.7%
Current Price
$3.93
Peak Price
$129
Trust Size
$173M
Summary
SAB Biotherapeutics is a clinical-stage biopharmaceutical company that uses genetically engineered cattle to produce fully human polyclonal antibodies for treating infectious diseases.
What Happened
SAB Biotherapeutics went public through a SPAC merger and trades under SABS. The company's novel DiversitAb platform uses transchromosomic cattle whose immune systems produce human antibodies when exposed to disease targets. SAB gained attention during COVID-19 for its potential therapeutic approach but has struggled to advance programs commercially, with the stock declining sharply and a reverse stock split executed.
Timeline
2021-01-04
S-1 Registration Filed
Risk Indicators
⚠️ Reverse Split